Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, Jonak C, Porkert S, Engelina S, Quaglino P, Ortiz-Romero PL, Vico C, Cozzio A, Dimitriou F, Guiron R, Guenova E, Hodak E, Bagot M, Scarisbrick J.
Papadavid E, et al. Among authors: dalamaga m.
Br J Dermatol. 2021 Nov;185(5):1035-1044. doi: 10.1111/bjd.20588. Epub 2021 Aug 17.
Br J Dermatol. 2021.
PMID: 34137025